Shares in Orexo AB fell more than 10 percent Tuesday on news that the Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc., was terminating an alliance to develop drugs targeting pathways involved in arachidonic acid metabolism. Read More

LONDON – A new method of probing the mechanisms of drug resistance in unicellular parasites has identified a tranche of genes and proteins that may make it possible to develop new treatments for hitherto difficult-to-treat infections. Read More

Prosensa Therapeutics BV raised €23 million (US$29.9 million) in a Series C round last week to enable it to move two new exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and to take forward preclinical programs in two other rare disease indications. Read More

Transgene SA is ramping up its engagement with China by establishing a wholly owned subsidiary called Transgene Biopharmaceuticals Technology (Shanghai) Co. Ltd., which will serve as a vehicle for its scientific collaboration with local academic research groups. Read More

LONDON – For once "unprecedented" was the mot juste as the CEOs of nine pharma and biotech companies took to the stage with government health and overseas aid ministers, and the heads of agencies including the World Health Organization (WHO) and the World Bank, to back the London Declaration, pledging to control or eliminate 10 neglected tropical diseases (NTDs) by 2020. Read More

• Circadian Technologies Ltd., of Melbourne, Australia, said preclinical data showed that VEGF-C blockade, through administration of Circadian's lead candidate VGX-100, a human antibody, significantly improved corneal graft survival in an animal model. Read More